Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
| DrugCom Name |
DrugCom ID |
Component Drug |
Indication |
REF |
|
ABIRATERONE + Indazole derivative 5
|
DC9XTHR
|
ABIRATERONE
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
ABIRATERONE + Indazole derivative 5
|
DCDKTRM
|
ABIRATERONE
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
ABIRATERONE + Indazole derivative 5
|
DCVHE9C
|
ABIRATERONE
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
ABIRATERONE + Indazole derivative 5
|
DCND3JP
|
ABIRATERONE
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
ABIRATERONE + Indazole derivative 5
|
DC98QNJ
|
ABIRATERONE
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
ABIRATERONE + Indazole derivative 5
|
DC2D5HA
|
ABIRATERONE
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
ABIRATERONE + Indazole derivative 5
|
DCDHIOL
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
ABIRATERONE + Indazole derivative 5
|
DCLYH34
|
ABIRATERONE
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
ABIRATERONE + Indazole derivative 5
|
DC7QNJW
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DCNNQHL
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DCWLZZW
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DCAOS0W
|
ABIRATERONE
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DC9F1R4
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DCHFFFZ
|
ABIRATERONE
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DCCJLTZ
|
ABIRATERONE
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DCEWESD
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DC1W04T
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DCI54IX
|
ABIRATERONE
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DCONUQQ
|
ABIRATERONE
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
ABIRATERONE + Indazole derivative 5
|
DCRUCY9
|
ABIRATERONE
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Cabazitaxel + Indazole derivative 5
|
DC1EEQD
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[1] |
|
Cabazitaxel + Indazole derivative 5
|
DCSUMFP
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCT-15)
|
[1] |
|
Cabazitaxel + Indazole derivative 5
|
DC6DFCH
|
Cabazitaxel
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Cabazitaxel + Indazole derivative 5
|
DCBOHYL
|
Cabazitaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Cabazitaxel + Indazole derivative 5
|
DC3TUPD
|
Cabazitaxel
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Cabazitaxel + Indazole derivative 5
|
DCDOMVJ
|
Cabazitaxel
|
Melanoma (Cell Line: MALME-3M)
|
[1] |
|
Cabazitaxel + Indazole derivative 5
|
DCQPLEC
|
Cabazitaxel
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCRZEHA
|
Crizotinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCI1DC0
|
Crizotinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DC38WSQ
|
Crizotinib
|
Adenocarcinoma (Cell Line: HCT-15)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCHL35T
|
Crizotinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DC4IAA4
|
Crizotinib
|
Amelanotic melanoma (Cell Line: M14)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCOOUNV
|
Crizotinib
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCG74HT
|
Crizotinib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCAX511
|
Crizotinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCXA1S9
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCZ8P08
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCPTET9
|
Crizotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCM5C8A
|
Crizotinib
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCWX1VA
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCL7C5U
|
Crizotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DC6B7XD
|
Crizotinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCZXKE7
|
Crizotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCJZ0NI
|
Crizotinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCOEOG0
|
Crizotinib
|
Melanoma (Cell Line: UACC-257)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DCAAASU
|
Crizotinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DC4S565
|
Crizotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Crizotinib + Indazole derivative 5
|
DC4MJ7Z
|
Crizotinib
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Crizotinib + Indazole derivative 5
|
DCAN6F2
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Crizotinib + Indazole derivative 5
|
DCFN9CO
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Crizotinib + Indazole derivative 5
|
DCOVV23
|
Crizotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Epirubicin + Indazole derivative 5
|
DCMFL7Y
|
Epirubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Epirubicin + Indazole derivative 5
|
DCWPWDO
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Epirubicin + Indazole derivative 5
|
DCFXP8Z
|
Epirubicin
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Epirubicin + Indazole derivative 5
|
DCXPV6K
|
Epirubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Epirubicin + Indazole derivative 5
|
DCQ01PE
|
Epirubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Epirubicin + Indazole derivative 5
|
DC3665Q
|
Epirubicin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Epirubicin + Indazole derivative 5
|
DCW3078
|
Epirubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Epirubicin + Indazole derivative 5
|
DCBIUQ5
|
Epirubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DC3CAOE
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCZL9WH
|
Epirubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCRVIAO
|
Epirubicin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DC56A9F
|
Epirubicin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCMK2TT
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCI7DPI
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCZWPQ1
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCJ9UNR
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCBJKIC
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCZUYZF
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCNDBC7
|
Epirubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCGA63F
|
Epirubicin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCI5VOA
|
Epirubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Epirubicin + Indazole derivative 5
|
DCU5HQA
|
Epirubicin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + Mechlorethamine
|
DC3GRIW
|
Mechlorethamine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Mechlorethamine
|
DCMR0AI
|
Mechlorethamine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Mechlorethamine
|
DCDEHKX
|
Mechlorethamine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Pentostatin
|
DCLU4B4
|
Pentostatin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Pentostatin
|
DCPBH2O
|
Pentostatin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Pentostatin
|
DCEP3B2
|
Pentostatin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Pentostatin
|
DCLXGVN
|
Pentostatin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Indazole derivative 5 + Picoplatin
|
DCTIH5X
|
Picoplatin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Fulvestrant
|
DC52X6V
|
Fulvestrant
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Fulvestrant
|
DCPSQT0
|
Fulvestrant
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Fulvestrant
|
DC9FEG2
|
Fulvestrant
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Gefitinib
|
DCLZ6SE
|
Gefitinib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Gefitinib
|
DCAT4E0
|
Gefitinib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Gefitinib
|
DCOJU35
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Gefitinib
|
DCFAVND
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Gefitinib
|
DCFMSEH
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Indazole derivative 5 + Gefitinib
|
DC6NHLR
|
Gefitinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Gefitinib
|
DCNDDDM
|
Gefitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Ruxolitinib
|
DCX3BWJ
|
Ruxolitinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Ruxolitinib
|
DCPNMGQ
|
Ruxolitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Hepzato
|
DC837P2
|
Hepzato
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Ixabepilone
|
DCBNCOE
|
Ixabepilone
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Ixabepilone
|
DCHH0H3
|
Ixabepilone
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Ixabepilone
|
DCMPH81
|
Ixabepilone
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCQ38LO
|
Dactinomycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DC3FARW
|
Dactinomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCRKZWP
|
Dactinomycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCVVEFU
|
Dactinomycin
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCBFJAB
|
Dactinomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DC6GSAV
|
Dactinomycin
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCFB407
|
Dactinomycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCK7RYH
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCPG0FW
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCZF3K2
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DC3EJFB
|
Dactinomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCBVF5A
|
Dactinomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCD062B
|
Dactinomycin
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DC1XA3F
|
Dactinomycin
|
Glioma (Cell Line: SF-295)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DC4Y0M8
|
Dactinomycin
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DC0AMZY
|
Dactinomycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCFK81K
|
Dactinomycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Dactinomycin
|
DCILQF2
|
Dactinomycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + DFN-15
|
DCH3W3Y
|
DFN-15
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + DFN-15
|
DCGG6OO
|
DFN-15
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + DFN-15
|
DCMO2OW
|
DFN-15
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Lapatinib
|
DCTO5KJ
|
Lapatinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCH0362
|
PMID28460551-Compound-2
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCB4GB6
|
PMID28460551-Compound-2
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Crizotinib
|
DC8KNJP
|
Crizotinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Crizotinib
|
DC99I14
|
Crizotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Crizotinib
|
DCGF7OD
|
Crizotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Cyclophosphamide
|
DCV4TI9
|
Cyclophosphamide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Cyclophosphamide
|
DCOGOBF
|
Cyclophosphamide
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Indazole derivative 5 + LIAROZOLE
|
DCMJUPQ
|
LIAROZOLE
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Methotrexate
|
DC7G92S
|
Methotrexate
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Indazole derivative 5 + Vismodegib
|
DC278L1
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Vismodegib
|
DC20AVU
|
Vismodegib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Vismodegib
|
DCYL9FS
|
Vismodegib
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Indazole derivative 5 + Isoniazid
|
DC9FLTK
|
Isoniazid
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Indazole derivative 5 + Isoniazid
|
DC2BWDJ
|
Isoniazid
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Isoniazid
|
DC25YBC
|
Isoniazid
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCUMFTB
|
Plicamycin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCPAJ95
|
Plicamycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCRHUXF
|
Plicamycin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DC9FAPK
|
Plicamycin
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DC6VYXF
|
Plicamycin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCF2XJ0
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DC3M1GY
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCB9QWN
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCQBU9J
|
Plicamycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCY0AHD
|
Plicamycin
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCHPYBC
|
Plicamycin
|
Glioma (Cell Line: SF-295)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCFJYS8
|
Plicamycin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCI9O4R
|
Plicamycin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Plicamycin
|
DCFAM6W
|
Plicamycin
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Indazole derivative 5 + Nilotinib
|
DC4TWTR
|
Nilotinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Nilotinib
|
DCB5KEM
|
Nilotinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Nilotinib
|
DC81TEI
|
Nilotinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Nilotinib
|
DCD5RTQ
|
Nilotinib
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + Thioguanine
|
DCCZA55
|
Thioguanine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Thioguanine
|
DCKFD6H
|
Thioguanine
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Indazole derivative 5 + Thioguanine
|
DCXQ9RK
|
Thioguanine
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Thioguanine
|
DC095FR
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Thioguanine
|
DC6727M
|
Thioguanine
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Thioguanine
|
DC0E3EP
|
Thioguanine
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Indazole derivative 5 + Thioguanine
|
DCVZXXR
|
Thioguanine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Indazole derivative 5 + Thioguanine
|
DCHVG4J
|
Thioguanine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Thioguanine
|
DC1T9VM
|
Thioguanine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + ABIRATERONE
|
DCRCGB2
|
ABIRATERONE
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Indazole derivative 5 + 10-hydroxycamptothecin
|
DCUIF1P
|
10-hydroxycamptothecin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + 10-hydroxycamptothecin
|
DCY7MXH
|
10-hydroxycamptothecin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + 10-hydroxycamptothecin
|
DCTIQOB
|
10-hydroxycamptothecin
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + 10-hydroxycamptothecin
|
DCP6MUO
|
10-hydroxycamptothecin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Topetecan
|
DCEP3YJ
|
Topetecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Amonafide
|
DCOF7D1
|
Amonafide
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Amonafide
|
DCRYF8A
|
Amonafide
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Pralatrexate
|
DCDX1HD
|
Pralatrexate
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Pralatrexate
|
DC6NUZ6
|
Pralatrexate
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Indazole derivative 5 + Pralatrexate
|
DCFL9OB
|
Pralatrexate
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Terameprocol
|
DCV87W6
|
Terameprocol
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Terameprocol
|
DCSUAG1
|
Terameprocol
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Terameprocol
|
DCQNXMZ
|
Terameprocol
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Indazole derivative 5 + Ifosfamide
|
DCOM71C
|
Ifosfamide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Ifosfamide
|
DCCLB8U
|
Ifosfamide
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Dexrazoxane
|
DCYT7UX
|
Dexrazoxane
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Dexrazoxane
|
DCR4H8W
|
Dexrazoxane
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Dexrazoxane
|
DCSM097
|
Dexrazoxane
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Dexrazoxane
|
DCJSI9A
|
Dexrazoxane
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Docetaxel
|
DCM2RXB
|
Docetaxel
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Docetaxel
|
DCOBZIS
|
Docetaxel
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Docetaxel
|
DCM919Y
|
Docetaxel
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Indazole derivative 5 + Docetaxel
|
DCXMRLK
|
Docetaxel
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Docetaxel
|
DCVP74X
|
Docetaxel
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Indazole derivative 5 + Docetaxel
|
DCG3HLH
|
Docetaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Docetaxel
|
DC63PSK
|
Docetaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Raloxifene
|
DCFF142
|
Raloxifene
|
Adenocarcinoma (Cell Line: HT29)
|
[1] |
|
Indazole derivative 5 + Raloxifene
|
DCFT565
|
Raloxifene
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Raloxifene
|
DCRORZ5
|
Raloxifene
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Raloxifene
|
DCOYVYF
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Raloxifene
|
DCZZLNA
|
Raloxifene
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Indazole derivative 5 + Raloxifene
|
DCTXNZJ
|
Raloxifene
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Raloxifene
|
DCX1KYU
|
Raloxifene
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCNQXAJ
|
Bendamustine hydrochloride
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCC2K7K
|
Bendamustine hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCLKMEJ
|
Bendamustine hydrochloride
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC5M0M4
|
Bendamustine hydrochloride
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCPLF0E
|
Bendamustine hydrochloride
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCTVHYH
|
Bendamustine hydrochloride
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC7GXKQ
|
Bendamustine hydrochloride
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCSHNL2
|
Bendamustine hydrochloride
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Indazole derivative 5 + Trifluridine
|
DCIKOE3
|
Trifluridine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Trifluridine
|
DC2SGLA
|
Trifluridine
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Trifluridine
|
DCYYMBG
|
Trifluridine
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Indazole derivative 5 + Trifluridine
|
DC78RPH
|
Trifluridine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + Sirolimus
|
DCLZRYB
|
Sirolimus
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Sirolimus
|
DC2QVWT
|
Sirolimus
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Sirolimus
|
DC4EHKI
|
Sirolimus
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Sirolimus
|
DC8UTUK
|
Sirolimus
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Indazole derivative 5 + Sirolimus
|
DCM7XAP
|
Sirolimus
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Sirolimus
|
DCS49OY
|
Sirolimus
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Sirolimus
|
DC0N2CW
|
Sirolimus
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Indazole derivative 5 + Sirolimus
|
DCYYZEK
|
Sirolimus
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + Mitomycin
|
DC3Z56V
|
Mitomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Mitomycin
|
DC5844F
|
Mitomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Mitomycin
|
DC7934S
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Mitomycin
|
DCF6APB
|
Mitomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Mitomycin
|
DCPD3PV
|
Mitomycin
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Indazole derivative 5 + SY-1425
|
DCEVVX6
|
SY-1425
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Uracil mustard
|
DCQ3Y10
|
Uracil mustard
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Uracil mustard
|
DC5U3NI
|
Uracil mustard
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Uracil mustard
|
DCSH966
|
Uracil mustard
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Uracil mustard
|
DC5IAIX
|
Uracil mustard
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Indazole derivative 5 + Uracil mustard
|
DCW50SF
|
Uracil mustard
|
Glioma (Cell Line: SF-295)
|
[1] |
|
Indazole derivative 5 + Vincristine
|
DC0BF6L
|
Vincristine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Vincristine
|
DCXY8WF
|
Vincristine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Arfolitixorin
|
DCQZN8Y
|
Arfolitixorin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Arfolitixorin
|
DC4TXOY
|
Arfolitixorin
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Arfolitixorin
|
DC6ATLE
|
Arfolitixorin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Arfolitixorin
|
DCA4SHD
|
Arfolitixorin
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Indazole derivative 5 + Arfolitixorin
|
DCNN8TM
|
Arfolitixorin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + BIO-300
|
DCVXFIO
|
BIO-300
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + BIO-300
|
DCYEWT2
|
BIO-300
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + BIO-300
|
DCKK021
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + BIO-300
|
DC5E3QL
|
BIO-300
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + BIO-300
|
DCPWJ5V
|
BIO-300
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Indazole derivative 5 + BIO-300
|
DCNOQ2A
|
BIO-300
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Indazole derivative 5 + Altretamine
|
DC7X4TY
|
Altretamine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Altretamine
|
DCFNHSB
|
Altretamine
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Altretamine
|
DCRWF3X
|
Altretamine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + TEM
|
DCVVLQT
|
TEM
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + JNK-IN-8
|
DC0XKUR
|
JNK-IN-8
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + JNK-IN-8
|
DCRDP1H
|
JNK-IN-8
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + JNK-IN-8
|
DCOHTNM
|
JNK-IN-8
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + Idarubicin
|
DCJEF9Z
|
Idarubicin
|
Glioblastoma? (Cell Line: T98G)
|
[1] |
|
Indazole derivative 5 + Imatinib
|
DCQZEO2
|
Imatinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Bleomycin
|
DC7I8ZO
|
Bleomycin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Bleomycin
|
DCWN7L4
|
Bleomycin
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Bleomycin
|
DC79SRO
|
Bleomycin
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Bleomycin
|
DC3H0SY
|
Bleomycin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Bleomycin
|
DCIL6Y3
|
Bleomycin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Bleomycin
|
DCAFGKS
|
Bleomycin
|
Glioblastoma (Cell Line: SNB-75)
|
[1] |
|
Indazole derivative 5 + Bleomycin
|
DCQYM71
|
Bleomycin
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + Bortezomib
|
DCB1SA7
|
Bortezomib
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Bortezomib
|
DCGUD5Y
|
Bortezomib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Bortezomib
|
DCWKGJI
|
Bortezomib
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Bortezomib
|
DCSGITM
|
Bortezomib
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Indazole derivative 5 + Bortezomib
|
DCGJ4OW
|
Bortezomib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Anastrozole
|
DCHKL29
|
Anastrozole
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Anastrozole
|
DCHGU51
|
Anastrozole
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Indazole derivative 5 + Anastrozole
|
DC8YIWZ
|
Anastrozole
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + Dacarbazine
|
DCKAAPE
|
Dacarbazine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Dacarbazine
|
DCYF0GR
|
Dacarbazine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Dacarbazine
|
DC7GFS4
|
Dacarbazine
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Dacarbazine
|
DCEM3B5
|
Dacarbazine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Dacarbazine
|
DC6ELHZ
|
Dacarbazine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Indazole derivative 5 + Dacarbazine
|
DC8UWPL
|
Dacarbazine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Valrubicin
|
DCCEUHI
|
Valrubicin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Valrubicin
|
DCOPYPK
|
Valrubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Topotecan
|
DCON5CJ
|
Topotecan
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Topotecan
|
DC9YGCX
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Topotecan
|
DC2BNOM
|
Topotecan
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Topotecan
|
DCMFRR2
|
Topotecan
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Indazole derivative 5 + Topotecan
|
DCWJQ5B
|
Topotecan
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Indazole derivative 5 + Cabazitaxel
|
DCREQYB
|
Cabazitaxel
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Indazole derivative 5 + Cabazitaxel
|
DCO9W0V
|
Cabazitaxel
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Cabazitaxel
|
DCXYR9G
|
Cabazitaxel
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Cabazitaxel
|
DCM887N
|
Cabazitaxel
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Indazole derivative 5 + Epirubicin
|
DCCOA1H
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Epirubicin
|
DC27J6K
|
Epirubicin
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Epirubicin
|
DCFGXUI
|
Epirubicin
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Indazole derivative 5 + Epirubicin
|
DC8Y5KI
|
Epirubicin
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Cisplatin
|
DCDHAU1
|
Cisplatin
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Vandetanib
|
DCN4Z2F
|
Vandetanib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Vandetanib
|
DCSL84C
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Vandetanib
|
DCVG7P8
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Vandetanib
|
DCT79XR
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Vandetanib
|
DCRLH3S
|
Vandetanib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Chlorambucil
|
DCEB2W6
|
Chlorambucil
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Chlorambucil
|
DC61HV7
|
Chlorambucil
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + ER819762
|
DC9JDHO
|
ER819762
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + ER819762
|
DCQN2QN
|
ER819762
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Romidepsin
|
DC933S2
|
Romidepsin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Romidepsin
|
DCSFP7T
|
Romidepsin
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Azacitidine
|
DC9XHDF
|
Azacitidine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Azacitidine
|
DCGMAJD
|
Azacitidine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Indazole derivative 5 + Pomalidomide
|
DCD4VBU
|
Pomalidomide
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Pomalidomide
|
DCVS791
|
Pomalidomide
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Indazole derivative 5 + Pomalidomide
|
DCMAOGC
|
Pomalidomide
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Indazole derivative 5 + Vinflunine
|
DCM44Q2
|
Vinflunine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Vinflunine
|
DCF5VPL
|
Vinflunine
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Indazole derivative 5 + Mepacrine
|
DCV7VGO
|
Mepacrine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Taxol
|
DCHDEOI
|
Taxol
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Taxol
|
DC1BPVF
|
Taxol
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Taxol
|
DCBIA53
|
Taxol
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Indazole derivative 5 + Taxol
|
DC85OCH
|
Taxol
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Taxol
|
DCI2YLE
|
Taxol
|
Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM)
|
[1] |
|
Indazole derivative 5 + Taxol
|
DCZAYAR
|
Taxol
|
Glioma (Cell Line: SF-539)
|
[1] |
|
Indazole derivative 5 + Fludarabine
|
DCX82J0
|
Fludarabine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Fludarabine
|
DC0BDS1
|
Fludarabine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Fludarabine
|
DCHD6Q6
|
Fludarabine
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Fludarabine
|
DCGSC9Z
|
Fludarabine
|
Renal cell carcinoma (Cell Line: SN12C)
|
[1] |
|
Indazole derivative 5 + FORMESTANE
|
DCIQWTC
|
FORMESTANE
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Indazole derivative 5 + Aminolevulinic Acid Hydrochloride
|
DC2QDGI
|
Aminolevulinic Acid Hydrochloride
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Aminolevulinic Acid Hydrochloride
|
DCBMN0J
|
Aminolevulinic Acid Hydrochloride
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Estramustine
|
DCLC8BF
|
Estramustine
|
Adult acute myeloid leukemia (Cell Line: HL-60(TB))
|
[1] |
|
Indazole derivative 5 + Estramustine
|
DCXG41K
|
Estramustine
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Estramustine
|
DCQPS6B
|
Estramustine
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Estramustine
|
DCNZ6EV
|
Estramustine
|
Astrocytoma (Cell Line: U251)
|
[1] |
|
Indazole derivative 5 + Estramustine
|
DCZUDJK
|
Estramustine
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Indazole derivative 5 + Estramustine
|
DCT80CT
|
Estramustine
|
Glioma (Cell Line: SF-268)
|
[1] |
|
Indazole derivative 5 + Estramustine
|
DC1CSVY
|
Estramustine
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Indazole derivative 5 + Estramustine
|
DC3F4SC
|
Estramustine
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Indazole derivative 5 + Estramustine
|
DCV001L
|
Estramustine
|
Renal cell carcinoma (Cell Line: UO-31)
|
[1] |
|
Indazole derivative 5 + Digitoxin
|
DCM306V
|
Digitoxin
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[1] |
|
Indazole derivative 5 + Digitoxin
|
DC90Z56
|
Digitoxin
|
Anaplastic large cell lymphoma (Cell Line: SR)
|
[1] |
|
Indazole derivative 5 + Dasatinib
|
DCA1VVG
|
Dasatinib
|
Adenocarcinoma (Cell Line: HT29)
|
[1] |
|
Indazole derivative 5 + Dasatinib
|
DCT9XEW
|
Dasatinib
|
Astrocytoma (Cell Line: SNB-19)
|
[1] |
|
Indazole derivative 5 + Dasatinib
|
DCUWP9H
|
Dasatinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Indazole derivative 5 + Dasatinib
|
DCTP4CI
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Indazole derivative 5 + Dasatinib
|
DCAQR7K
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[1] |
|
Indazole derivative 5 + Dasatinib
|
DCF0UQD
|
Dasatinib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[1] |
|
Indazole derivative 5 + Pentostatin
|
DCXZ4PK
|
Pentostatin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + Pentostatin
|
DC0PW11
|
Pentostatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Picoplatin
|
DC7ELMF
|
Picoplatin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Fulvestrant
|
DC5LOGL
|
Fulvestrant
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + Fulvestrant
|
DC63X0Q
|
Fulvestrant
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Fulvestrant
|
DC9GJFF
|
Fulvestrant
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Fulvestrant
|
DCTR96X
|
Fulvestrant
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Gefitinib
|
DCVVSC9
|
Gefitinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Gefitinib
|
DC4F0SZ
|
Gefitinib
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Gefitinib
|
DCN312B
|
Gefitinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Ruxolitinib
|
DCO4U0N
|
Ruxolitinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Ruxolitinib
|
DCAFVBT
|
Ruxolitinib
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + Ruxolitinib
|
DCPKVRD
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Hepzato
|
DC4NK4W
|
Hepzato
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Ixabepilone
|
DCKIFQ5
|
Ixabepilone
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Ixabepilone
|
DCL16MC
|
Ixabepilone
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Dactinomycin
|
DC6D6X7
|
Dactinomycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Dactinomycin
|
DCJ2DBP
|
Dactinomycin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + Dactinomycin
|
DCF6T15
|
Dactinomycin
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Dactinomycin
|
DCJWUHE
|
Dactinomycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Dactinomycin
|
DCGJXS0
|
Dactinomycin
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + Dactinomycin
|
DCQTF6F
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Indazole derivative 5 + Dactinomycin
|
DC5WU98
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Dactinomycin
|
DC3QNUD
|
Dactinomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + DFN-15
|
DCYTCR5
|
DFN-15
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Lapatinib
|
DCB7C2C
|
Lapatinib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCPHEAQ
|
PMID28460551-Compound-2
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + Crizotinib
|
DC7AWS6
|
Crizotinib
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + LIAROZOLE
|
DC4G1PH
|
LIAROZOLE
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + Methotrexate
|
DCADNYR
|
Methotrexate
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Isoniazid
|
DCDICLN
|
Isoniazid
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Vemurafenib
|
DCVP7FR
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Lenalidomide
|
DCC0P93
|
Lenalidomide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Plicamycin
|
DC4KB76
|
Plicamycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Plicamycin
|
DCNT3XE
|
Plicamycin
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Plicamycin
|
DCCAG7O
|
Plicamycin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Plicamycin
|
DC62AHJ
|
Plicamycin
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + Plicamycin
|
DCO8X0V
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Plicamycin
|
DCK3F0N
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Plicamycin
|
DCDMYCJ
|
Plicamycin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Indazole derivative 5 + Nilotinib
|
DC49RWB
|
Nilotinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Thioguanine
|
DCQ5YCI
|
Thioguanine
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Thioguanine
|
DC6E323
|
Thioguanine
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Thioguanine
|
DCBWA7G
|
Thioguanine
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + ABIRATERONE
|
DCKEH6T
|
ABIRATERONE
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + ABIRATERONE
|
DCZLSL4
|
ABIRATERONE
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Terameprocol
|
DC12K85
|
Terameprocol
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + Terameprocol
|
DCUX42S
|
Terameprocol
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Terameprocol
|
DC5OXWP
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Terameprocol
|
DC217OB
|
Terameprocol
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + SCH 727965
|
DCVZ3BN
|
SCH 727965
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Ifosfamide
|
DCUO996
|
Ifosfamide
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Ifosfamide
|
DCSPK7E
|
Ifosfamide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Ifosfamide
|
DCY8BSD
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Ifosfamide
|
DCY9FO1
|
Ifosfamide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCRFG0B
|
Raloxifene
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCNYUWF
|
Raloxifene
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DCEJUMO
|
Raloxifene
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DC165T1
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DC49MQF
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Raloxifene
|
DC5FTAJ
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCEELBR
|
Bendamustine hydrochloride
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCFVNRS
|
Bendamustine hydrochloride
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC7UVX4
|
Bendamustine hydrochloride
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Trifluridine
|
DCUIGXT
|
Trifluridine
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + Trifluridine
|
DC3YSO9
|
Trifluridine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Sirolimus
|
DCGWKZT
|
Sirolimus
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + Sirolimus
|
DC5HXWA
|
Sirolimus
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Indazole derivative 5 + Letrozole
|
DCBVMI1
|
Letrozole
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Letrozole
|
DCA5D92
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Letrozole
|
DCGHF9E
|
Letrozole
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Mitomycin
|
DCHOQJS
|
Mitomycin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + Mitomycin
|
DCBWL3U
|
Mitomycin
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + Mitomycin
|
DCFWBRY
|
Mitomycin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + SY-1425
|
DCV3P1T
|
SY-1425
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + SY-1425
|
DC1T48L
|
SY-1425
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Uracil mustard
|
DCTVD7G
|
Uracil mustard
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + Arfolitixorin
|
DCUDBPP
|
Arfolitixorin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Arfolitixorin
|
DCBPQE0
|
Arfolitixorin
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + Arfolitixorin
|
DCYLNE3
|
Arfolitixorin
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + BIO-300
|
DCX77FK
|
BIO-300
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + Altretamine
|
DCLJNXC
|
Altretamine
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Altretamine
|
DCGX5DQ
|
Altretamine
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + TEM
|
DCJ9UAA
|
TEM
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + TEM
|
DCXPTRU
|
TEM
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + TEM
|
DCNQZ7E
|
TEM
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + JNK-IN-8
|
DCF3PJU
|
JNK-IN-8
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + JNK-IN-8
|
DCSCXT6
|
JNK-IN-8
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + Idarubicin
|
DCDEVNM
|
Idarubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Imatinib
|
DCE8LJI
|
Imatinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Bleomycin
|
DCVZL2H
|
Bleomycin
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Anastrozole
|
DCQIN1C
|
Anastrozole
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Dacarbazine
|
DC0X2JR
|
Dacarbazine
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + Dacarbazine
|
DCHTB3L
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Indazole derivative 5 + Dacarbazine
|
DCZWCCU
|
Dacarbazine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Valrubicin
|
DCJEEJ2
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Valrubicin
|
DCPDFZD
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Valrubicin
|
DCYVMRB
|
Valrubicin
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Indazole derivative 5 + Topotecan
|
DCN3EKC
|
Topotecan
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Topotecan
|
DCT3KZB
|
Topotecan
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Topotecan
|
DCZY7A4
|
Topotecan
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Cabazitaxel
|
DCAJZV9
|
Cabazitaxel
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Indazole derivative 5 + Epirubicin
|
DC4LL4G
|
Epirubicin
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Epirubicin
|
DC0AQH1
|
Epirubicin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Cisplatin
|
DC0FGQR
|
Cisplatin
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Cisplatin
|
DCT2WNG
|
Cisplatin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Vandetanib
|
DCVEXM8
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + ER819762
|
DC8GPUH
|
ER819762
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Pomalidomide
|
DC5MGZS
|
Pomalidomide
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + Pomalidomide
|
DCB7BS8
|
Pomalidomide
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Pomalidomide
|
DCA8X0H
|
Pomalidomide
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + Taxol
|
DC8RCVM
|
Taxol
|
Colon carcinoma (Cell Line: KM12)
|
[2] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCEM46Q
|
PMID28870136-Compound-43
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Indazole derivative 5 + FORMESTANE
|
DCCREDV
|
FORMESTANE
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Indazole derivative 5 + FORMESTANE
|
DCNRZ8B
|
FORMESTANE
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Estramustine
|
DCHB54N
|
Estramustine
|
Carcinoma (Cell Line: RXF 393)
|
[2] |
|
Indazole derivative 5 + Estramustine
|
DC6YA5I
|
Estramustine
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Digitoxin
|
DCASYIT
|
Digitoxin
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Indazole derivative 5 + Digitoxin
|
DCG4HOI
|
Digitoxin
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Indazole derivative 5 + Mechlorethamine
|
DCBZQM5
|
Mechlorethamine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Pentostatin
|
DC2E25E
|
Pentostatin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + Pentostatin
|
DCEENUE
|
Pentostatin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Pentostatin
|
DCTUXBK
|
Pentostatin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Indazole derivative 5 + Pentostatin
|
DCIGVM2
|
Pentostatin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Pentostatin
|
DCQILY4
|
Pentostatin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Pentostatin
|
DCQ3ZUH
|
Pentostatin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Pentostatin
|
DCL2UOU
|
Pentostatin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Picoplatin
|
DC6BKTF
|
Picoplatin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + Fulvestrant
|
DCPIDBQ
|
Fulvestrant
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + Fulvestrant
|
DCG9COC
|
Fulvestrant
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Fulvestrant
|
DCVY30W
|
Fulvestrant
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Indazole derivative 5 + Fulvestrant
|
DC3PXBF
|
Fulvestrant
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + Fulvestrant
|
DCT23DT
|
Fulvestrant
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Fulvestrant
|
DCORU04
|
Fulvestrant
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Fulvestrant
|
DCRVS3D
|
Fulvestrant
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Fulvestrant
|
DCJ253K
|
Fulvestrant
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Fulvestrant
|
DC72BWZ
|
Fulvestrant
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Fulvestrant
|
DCNVEW5
|
Fulvestrant
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DC2UBFG
|
Gefitinib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DCGEL7L
|
Gefitinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DCIH8W8
|
Gefitinib
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DCFGCNS
|
Gefitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DC6U6YN
|
Gefitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DC4MJKQ
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DCOZK7B
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DC5K9RP
|
Gefitinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DCHGM7H
|
Gefitinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DCANLNT
|
Gefitinib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DCY4YE5
|
Gefitinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DCK4N64
|
Gefitinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + Gefitinib
|
DCIM6GE
|
Gefitinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Ruxolitinib
|
DCAJ1J1
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Ruxolitinib
|
DCA99Z9
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + Ruxolitinib
|
DCGGSSH
|
Ruxolitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Ruxolitinib
|
DCZTDP6
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Ruxolitinib
|
DCOCUF1
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Ruxolitinib
|
DCCS6FG
|
Ruxolitinib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Ruxolitinib
|
DCIGYFX
|
Ruxolitinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Ruxolitinib
|
DCDNMXF
|
Ruxolitinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Ruxolitinib
|
DC9ELFW
|
Ruxolitinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Ruxolitinib
|
DC97U96
|
Ruxolitinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCY0F38
|
Hepzato
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCXLI4K
|
Hepzato
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCHGV5M
|
Hepzato
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCBOFN4
|
Hepzato
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCWX2JC
|
Hepzato
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DC5Y0IP
|
Hepzato
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCHSWIB
|
Hepzato
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCZMWMO
|
Hepzato
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Hepzato
|
DCNNUUT
|
Hepzato
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Ixabepilone
|
DCUNQTL
|
Ixabepilone
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Indazole derivative 5 + Ixabepilone
|
DC67G6T
|
Ixabepilone
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Ixabepilone
|
DCLTWKM
|
Ixabepilone
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DC0BPNY
|
Dactinomycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DC99BM4
|
Dactinomycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCXWNW4
|
Dactinomycin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DC31TEY
|
Dactinomycin
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCMH7RS
|
Dactinomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCFO0DJ
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DC67L8H
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCYFGPB
|
Dactinomycin
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCDKGBO
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCS4TU2
|
Dactinomycin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCFZB3E
|
Dactinomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCHH06L
|
Dactinomycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCXSLSE
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCT3HCW
|
Dactinomycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCGRP4E
|
Dactinomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DC38C9P
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCD97AG
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCOWYXD
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCVANDD
|
Dactinomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DC075P0
|
Dactinomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DC5GDJA
|
Dactinomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCMFSLX
|
Dactinomycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DC36NDK
|
Dactinomycin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCWJCIC
|
Dactinomycin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCAFBC7
|
Dactinomycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCU4M13
|
Dactinomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCWIU2H
|
Dactinomycin
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DC36UH4
|
Dactinomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCMVWYH
|
Dactinomycin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Indazole derivative 5 + Dactinomycin
|
DCKLOF3
|
Dactinomycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DCQI8M3
|
DFN-15
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DCUAPXD
|
DFN-15
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DC8PO7S
|
DFN-15
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DCETGFL
|
DFN-15
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DCGPRM3
|
DFN-15
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DCX0IL5
|
DFN-15
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DCT0GME
|
DFN-15
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DC32L2P
|
DFN-15
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DCWW6BL
|
DFN-15
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + DFN-15
|
DC0V8ZE
|
DFN-15
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Lapatinib
|
DC8XI4I
|
Lapatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Lapatinib
|
DCWAL30
|
Lapatinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCUMIKE
|
PMID28460551-Compound-2
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCL4ET4
|
PMID28460551-Compound-2
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DCE5MTT
|
PMID28460551-Compound-2
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + PMID28460551-Compound-2
|
DC7YJ8R
|
PMID28460551-Compound-2
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Crizotinib
|
DCL67R1
|
Crizotinib
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Indazole derivative 5 + Crizotinib
|
DCZDG5P
|
Crizotinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Crizotinib
|
DC5GSAQ
|
Crizotinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Cyclophosphamide
|
DCQ9PLO
|
Cyclophosphamide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Cyclophosphamide
|
DCZLJBT
|
Cyclophosphamide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Cyclophosphamide
|
DCIQPJB
|
Cyclophosphamide
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Indazole derivative 5 + Vismodegib
|
DCNHS0X
|
Vismodegib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Vismodegib
|
DCLRBFF
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Vismodegib
|
DCBSWML
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Indazole derivative 5 + Vismodegib
|
DCC6PFK
|
Vismodegib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Vismodegib
|
DCZJLI5
|
Vismodegib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Vismodegib
|
DCQSE7N
|
Vismodegib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Isoniazid
|
DC9J0VL
|
Isoniazid
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Isoniazid
|
DC8NFDA
|
Isoniazid
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Isoniazid
|
DCUCZ50
|
Isoniazid
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Isoniazid
|
DC8XQL1
|
Isoniazid
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Isoniazid
|
DC0AZ5Z
|
Isoniazid
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Isoniazid
|
DC6SOKU
|
Isoniazid
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Vemurafenib
|
DCE6L26
|
Vemurafenib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Vemurafenib
|
DCS9WPC
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Vemurafenib
|
DCR38V3
|
Vemurafenib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Lenalidomide
|
DCG1728
|
Lenalidomide
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Lenalidomide
|
DC7OEZS
|
Lenalidomide
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCZG6WP
|
Plicamycin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCCCLGJ
|
Plicamycin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DC4Q8XF
|
Plicamycin
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DC659YG
|
Plicamycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCDCF5O
|
Plicamycin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DC8EKGK
|
Plicamycin
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCW5TKR
|
Plicamycin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCHTQRX
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCXFSYB
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCDLKVS
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DC1V6R7
|
Plicamycin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DC4DQKT
|
Plicamycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCKJGRV
|
Plicamycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCU5XVY
|
Plicamycin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCEHX1L
|
Plicamycin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DC66JV2
|
Plicamycin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DC3LJKY
|
Plicamycin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DCUTBHH
|
Plicamycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DC32BYX
|
Plicamycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Plicamycin
|
DC1XBEP
|
Plicamycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + Nilotinib
|
DCT2SDA
|
Nilotinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Nilotinib
|
DCLADWD
|
Nilotinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Nilotinib
|
DCNWOFG
|
Nilotinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Nilotinib
|
DCU11K4
|
Nilotinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Nilotinib
|
DC9GOG9
|
Nilotinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Indazole derivative 5 + Nilotinib
|
DCL9UK6
|
Nilotinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + Thioguanine
|
DCAZAEC
|
Thioguanine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + Thioguanine
|
DC5CSZQ
|
Thioguanine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Indazole derivative 5 + Thioguanine
|
DCW28K1
|
Thioguanine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Thioguanine
|
DC2BG9R
|
Thioguanine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Thioguanine
|
DCMUGY7
|
Thioguanine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Thioguanine
|
DCR2P4D
|
Thioguanine
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Triapine
|
DC7J5U4
|
Triapine
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Triapine
|
DCF4KKK
|
Triapine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Triapine
|
DCPIDXI
|
Triapine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Triapine
|
DC2HOH6
|
Triapine
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + ABIRATERONE
|
DCIOSIR
|
ABIRATERONE
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + ABIRATERONE
|
DCVUN1Q
|
ABIRATERONE
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + ABIRATERONE
|
DCHXB5F
|
ABIRATERONE
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + ABIRATERONE
|
DCSY3UG
|
ABIRATERONE
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + ABIRATERONE
|
DCJRXF3
|
ABIRATERONE
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + 10-hydroxycamptothecin
|
DCQJB7F
|
10-hydroxycamptothecin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Indazole derivative 5 + 10-hydroxycamptothecin
|
DC0UAJZ
|
10-hydroxycamptothecin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + 10-hydroxycamptothecin
|
DCH4LEY
|
10-hydroxycamptothecin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Pralatrexate
|
DCEYO90
|
Pralatrexate
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + Pralatrexate
|
DCRLRPD
|
Pralatrexate
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Indazole derivative 5 + Pralatrexate
|
DC0CLGE
|
Pralatrexate
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Indazole derivative 5 + Pralatrexate
|
DCPTMXH
|
Pralatrexate
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Pralatrexate
|
DC9TAXZ
|
Pralatrexate
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DC9SH51
|
Terameprocol
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCIMZ2J
|
Terameprocol
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCVQ2K0
|
Terameprocol
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DC0RCV4
|
Terameprocol
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCCD82J
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCPFLPO
|
Terameprocol
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCRJ3J5
|
Terameprocol
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCRTPNL
|
Terameprocol
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCR8L8L
|
Terameprocol
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCRHAR1
|
Terameprocol
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCWZWBU
|
Terameprocol
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCIHAEI
|
Terameprocol
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Indazole derivative 5 + Terameprocol
|
DCZHKYJ
|
Terameprocol
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + SCH 727965
|
DC7BSTO
|
SCH 727965
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + SCH 727965
|
DCGJB50
|
SCH 727965
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + SCH 727965
|
DCTL4QT
|
SCH 727965
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Ifosfamide
|
DCJEQF5
|
Ifosfamide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Ifosfamide
|
DCJWLG0
|
Ifosfamide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Indazole derivative 5 + Ifosfamide
|
DCW0QXX
|
Ifosfamide
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Ifosfamide
|
DCNTV10
|
Ifosfamide
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Ifosfamide
|
DCRZMV0
|
Ifosfamide
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Ifosfamide
|
DCKYPVY
|
Ifosfamide
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Ifosfamide
|
DCK4Z2Z
|
Ifosfamide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + Ifosfamide
|
DC051KL
|
Ifosfamide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Dexrazoxane
|
DCQT1SP
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Indazole derivative 5 + Dexrazoxane
|
DCQJ4NZ
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + Dexrazoxane
|
DC099RO
|
Dexrazoxane
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + Dexrazoxane
|
DC3I94A
|
Dexrazoxane
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Docetaxel
|
DCEDNOS
|
Docetaxel
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Indazole derivative 5 + Docetaxel
|
DC2JHYX
|
Docetaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Indazole derivative 5 + Docetaxel
|
DCC1UPW
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Indazole derivative 5 + Docetaxel
|
DCGPDQ1
|
Docetaxel
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + Docetaxel
|
DCUGV99
|
Docetaxel
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Docetaxel
|
DCWEOOZ
|
Docetaxel
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCDXGEG
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCVDV3K
|
Raloxifene
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCG0SN2
|
Raloxifene
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DC7WU5Z
|
Raloxifene
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCBOEH0
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCWYMLD
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCLNSSQ
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCYKGJ7
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DC0SEVB
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DC4GZS6
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCYY8VP
|
Raloxifene
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCVAC2X
|
Raloxifene
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DCUQYGQ
|
Raloxifene
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DC6R3W0
|
Raloxifene
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DC8E7KZ
|
Raloxifene
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Raloxifene
|
DC1ONYO
|
Raloxifene
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCGIG35
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCW73IU
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC5W7PV
|
Bendamustine hydrochloride
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC9ABPF
|
Bendamustine hydrochloride
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCE7U6R
|
Bendamustine hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCAMH45
|
Bendamustine hydrochloride
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCYQKVK
|
Bendamustine hydrochloride
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCOF4HC
|
Bendamustine hydrochloride
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCDS81C
|
Bendamustine hydrochloride
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCH3PT9
|
Bendamustine hydrochloride
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DC90OUO
|
Bendamustine hydrochloride
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Bendamustine hydrochloride
|
DCD2BDR
|
Bendamustine hydrochloride
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + Trifluridine
|
DCNC60R
|
Trifluridine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Trifluridine
|
DC0WG0B
|
Trifluridine
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Trifluridine
|
DCY35VT
|
Trifluridine
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Sirolimus
|
DCRCP1F
|
Sirolimus
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Indazole derivative 5 + Sirolimus
|
DCMSSP4
|
Sirolimus
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + Sirolimus
|
DC9FMWN
|
Sirolimus
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Indazole derivative 5 + Sirolimus
|
DC6RD8W
|
Sirolimus
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Sirolimus
|
DCIT16C
|
Sirolimus
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Sirolimus
|
DC5JY5X
|
Sirolimus
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Sirolimus
|
DC8J74F
|
Sirolimus
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Sirolimus
|
DCH9UPD
|
Sirolimus
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Indazole derivative 5 + Letrozole
|
DCP3KFD
|
Letrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Letrozole
|
DC4TFZV
|
Letrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Indazole derivative 5 + Letrozole
|
DC9RXDP
|
Letrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Letrozole
|
DC1KVTG
|
Letrozole
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Letrozole
|
DCM8JXE
|
Letrozole
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Letrozole
|
DCB2K6O
|
Letrozole
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Mitomycin
|
DCIYWZX
|
Mitomycin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + Mitomycin
|
DC8FKX1
|
Mitomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Indazole derivative 5 + Mitomycin
|
DC0HPV2
|
Mitomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Indazole derivative 5 + Mitomycin
|
DCMQDHF
|
Mitomycin
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Indazole derivative 5 + Mitomycin
|
DCMVAXI
|
Mitomycin
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Mitomycin
|
DCRMB15
|
Mitomycin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + SY-1425
|
DCDPZ9D
|
SY-1425
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + SY-1425
|
DC0CYTT
|
SY-1425
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + SY-1425
|
DCJMRG8
|
SY-1425
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + SY-1425
|
DCR1ZDL
|
SY-1425
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + Uracil mustard
|
DCQJXKW
|
Uracil mustard
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Uracil mustard
|
DCE9XTK
|
Uracil mustard
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Uracil mustard
|
DCXM1F4
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Indazole derivative 5 + Uracil mustard
|
DCIYHHR
|
Uracil mustard
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Uracil mustard
|
DCSWWEM
|
Uracil mustard
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Indazole derivative 5 + Vincristine
|
DCPKADF
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Indazole derivative 5 + Vincristine
|
DC4ZRU5
|
Vincristine
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + Vincristine
|
DCJ7Y6E
|
Vincristine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Vincristine
|
DCETF9I
|
Vincristine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Vincristine
|
DCHA12A
|
Vincristine
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Indazole derivative 5 + Arfolitixorin
|
DCLFUE5
|
Arfolitixorin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + Arfolitixorin
|
DCSP1YC
|
Arfolitixorin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Arfolitixorin
|
DCT9LBC
|
Arfolitixorin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCQL98S
|
BIO-300
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCF9LRM
|
BIO-300
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCO560Z
|
BIO-300
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DC272VJ
|
BIO-300
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCHNDU0
|
BIO-300
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + BIO-300
|
DCVJNI1
|
BIO-300
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Altretamine
|
DCM7E7J
|
Altretamine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Indazole derivative 5 + Altretamine
|
DCFVWCF
|
Altretamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Altretamine
|
DCLLH17
|
Altretamine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Altretamine
|
DCGEU84
|
Altretamine
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + TEM
|
DCV19MO
|
TEM
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + TEM
|
DCCB258
|
TEM
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + TEM
|
DC7I5VT
|
TEM
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + TEM
|
DCIJ9XK
|
TEM
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + TEM
|
DC39CXQ
|
TEM
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + TEM
|
DCLANZG
|
TEM
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + TEM
|
DCRHE85
|
TEM
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + TEM
|
DCE56V4
|
TEM
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + TEM
|
DCVFD3V
|
TEM
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + JNK-IN-8
|
DCGB05J
|
JNK-IN-8
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + JNK-IN-8
|
DCE4SQR
|
JNK-IN-8
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + JNK-IN-8
|
DCIUNWV
|
JNK-IN-8
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + Imatinib
|
DC85YZE
|
Imatinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Imatinib
|
DC0WTD1
|
Imatinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + Bleomycin
|
DCP663P
|
Bleomycin
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Indazole derivative 5 + Bleomycin
|
DC67VHN
|
Bleomycin
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + Bleomycin
|
DCNQORV
|
Bleomycin
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Bleomycin
|
DCLJLFK
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Indazole derivative 5 + Bleomycin
|
DC9KK61
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Indazole derivative 5 + Bleomycin
|
DCZ63K7
|
Bleomycin
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Bleomycin
|
DCDXJN8
|
Bleomycin
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Bleomycin
|
DCVERL9
|
Bleomycin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Bortezomib
|
DCQ43FU
|
Bortezomib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Bortezomib
|
DCT0GMC
|
Bortezomib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Bortezomib
|
DCONHZO
|
Bortezomib
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Anastrozole
|
DCI14W2
|
Anastrozole
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + Anastrozole
|
DCIGAQL
|
Anastrozole
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Anastrozole
|
DCIKO8B
|
Anastrozole
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Anastrozole
|
DCMF5PD
|
Anastrozole
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Anastrozole
|
DCIR1Q5
|
Anastrozole
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Dacarbazine
|
DCGBNKW
|
Dacarbazine
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + Dacarbazine
|
DCXQABI
|
Dacarbazine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Dacarbazine
|
DCHCWC9
|
Dacarbazine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Dacarbazine
|
DCBA01I
|
Dacarbazine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Dacarbazine
|
DCGBKD3
|
Dacarbazine
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + Dacarbazine
|
DC8UH00
|
Dacarbazine
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Valrubicin
|
DCKID3R
|
Valrubicin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Valrubicin
|
DCZLM7U
|
Valrubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Valrubicin
|
DCVMIGK
|
Valrubicin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Valrubicin
|
DCNWCV0
|
Valrubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Valrubicin
|
DCFJY11
|
Valrubicin
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Valrubicin
|
DC96N5K
|
Valrubicin
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DCLDV8J
|
Topotecan
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DCMBLB9
|
Topotecan
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DC2XWA1
|
Topotecan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DCD3UP4
|
Topotecan
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DCXTOD2
|
Topotecan
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DC47JNC
|
Topotecan
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DCMC289
|
Topotecan
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DC8FJ3G
|
Topotecan
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DCFCJWW
|
Topotecan
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DCY64ET
|
Topotecan
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Indazole derivative 5 + Topotecan
|
DCCQXYW
|
Topotecan
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + Cabazitaxel
|
DCKHD9I
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Indazole derivative 5 + Cabazitaxel
|
DC14B5J
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Indazole derivative 5 + Cabazitaxel
|
DC0XVOC
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + Cabazitaxel
|
DCGIYSY
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: HCT116)
|
[3] |
|
Indazole derivative 5 + Cabazitaxel
|
DC23CXH
|
Cabazitaxel
|
Adenocarcinoma (Cell Line: SW-620)
|
[3] |
|
Indazole derivative 5 + Cabazitaxel
|
DCIPZ72
|
Cabazitaxel
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Cabazitaxel
|
DC8J6XA
|
Cabazitaxel
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Cabazitaxel
|
DCACGL6
|
Cabazitaxel
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Indazole derivative 5 + Cabazitaxel
|
DCT048N
|
Cabazitaxel
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DCYZ4RD
|
Epirubicin
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DC53D9Y
|
Epirubicin
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DCHLRW4
|
Epirubicin
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DCSFYKM
|
Epirubicin
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DCXS0OC
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DC7VFRF
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DCB1CTU
|
Epirubicin
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DCM0G4M
|
Epirubicin
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DC86KGD
|
Epirubicin
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DCJB1QB
|
Epirubicin
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Epirubicin
|
DCB81B3
|
Epirubicin
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Cisplatin
|
DCHDXSC
|
Cisplatin
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + Cisplatin
|
DCYY0P4
|
Cisplatin
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Indazole derivative 5 + Cisplatin
|
DCICGG6
|
Cisplatin
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + Vandetanib
|
DC9OKYI
|
Vandetanib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Vandetanib
|
DCXJSG8
|
Vandetanib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Chlorambucil
|
DC3RID1
|
Chlorambucil
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Chlorambucil
|
DC2W54V
|
Chlorambucil
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + Sorafenib
|
DCFPTMO
|
Sorafenib
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + ER819762
|
DCX87SK
|
ER819762
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + ER819762
|
DCMV28J
|
ER819762
|
Malignant melanoma (Cell Line: LOX IMVI)
|
[3] |
|
Indazole derivative 5 + ER819762
|
DCU13M7
|
ER819762
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + Romidepsin
|
DCBPA5F
|
Romidepsin
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Indazole derivative 5 + Azacitidine
|
DCKQ4GS
|
Azacitidine
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Azacitidine
|
DCAPNDI
|
Azacitidine
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DCC6U60
|
Pomalidomide
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DC6SVTS
|
Pomalidomide
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DCWYOS2
|
Pomalidomide
|
Adenocarcinoma (Cell Line: HT29)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DCJAPON
|
Pomalidomide
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DCKPCNO
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DC8USQL
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DC9P78U
|
Pomalidomide
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DC3IS2M
|
Pomalidomide
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DC8S74I
|
Pomalidomide
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DCNP5SI
|
Pomalidomide
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Indazole derivative 5 + Pomalidomide
|
DCTYX8C
|
Pomalidomide
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Indazole derivative 5 + Vinflunine
|
DCDRWS3
|
Vinflunine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Mercaptopurine
|
DCBBAI9
|
Mercaptopurine
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + Mepacrine
|
DCJXFOH
|
Mepacrine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Taxol
|
DC1KST3
|
Taxol
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Indazole derivative 5 + Taxol
|
DCUHXAD
|
Taxol
|
Adenocarcinoma (Cell Line: HCC-2998)
|
[3] |
|
Indazole derivative 5 + Taxol
|
DC33V27
|
Taxol
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Indazole derivative 5 + Taxol
|
DCRFBF0
|
Taxol
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Taxol
|
DCJJQDP
|
Taxol
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DC76XZC
|
PMID28870136-Compound-43
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DC3TPS7
|
PMID28870136-Compound-43
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCYCUV5
|
PMID28870136-Compound-43
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCRREFN
|
PMID28870136-Compound-43
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DC7HC64
|
PMID28870136-Compound-43
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCJ5GXG
|
PMID28870136-Compound-43
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCWW2IL
|
PMID28870136-Compound-43
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCSW4HB
|
PMID28870136-Compound-43
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Indazole derivative 5 + PMID28870136-Compound-43
|
DCYR31G
|
PMID28870136-Compound-43
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Indazole derivative 5 + FORMESTANE
|
DCZXIPW
|
FORMESTANE
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + FORMESTANE
|
DCTF86O
|
FORMESTANE
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + FORMESTANE
|
DC94PNA
|
FORMESTANE
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + FORMESTANE
|
DCCAOBU
|
FORMESTANE
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Indazole derivative 5 + FORMESTANE
|
DC7TVHL
|
FORMESTANE
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Indazole derivative 5 + Aminolevulinic Acid Hydrochloride
|
DCVTF4M
|
Aminolevulinic Acid Hydrochloride
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Indazole derivative 5 + Aminolevulinic Acid Hydrochloride
|
DCM6GU9
|
Aminolevulinic Acid Hydrochloride
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Estramustine
|
DCW0NXL
|
Estramustine
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Indazole derivative 5 + Estramustine
|
DCGPPVP
|
Estramustine
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Indazole derivative 5 + Estramustine
|
DC2W91P
|
Estramustine
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Estramustine
|
DC53RD4
|
Estramustine
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Estramustine
|
DCGJNWU
|
Estramustine
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Estramustine
|
DCK45JK
|
Estramustine
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Digitoxin
|
DCLPJNS
|
Digitoxin
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Indazole derivative 5 + Busulfan
|
DC2NOC9
|
Busulfan
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Dasatinib
|
DCQO3YR
|
Dasatinib
|
Adenocarcinoma (Cell Line: A549)
|
[3] |
|
Indazole derivative 5 + Dasatinib
|
DC89GDM
|
Dasatinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Indazole derivative 5 + Dasatinib
|
DCW8KR7
|
Dasatinib
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Indazole derivative 5 + Dasatinib
|
DCS4O5F
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Indazole derivative 5 + Dasatinib
|
DCGGPNC
|
Dasatinib
|
Lung adenocarcinoma (Cell Line: NCI-H522)
|
[3] |
|
Indazole derivative 5 + Dasatinib
|
DC0PNZS
|
Dasatinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Indazole derivative 5 + Dasatinib
|
DCD7Y8V
|
Dasatinib
|
Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1)
|
[3] |
|
Indazole derivative 5 + Dasatinib
|
DCEI01Y
|
Dasatinib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Indazole derivative 5 + Dasatinib
|
DCNYCK2
|
Dasatinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCUBDT0
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Raloxifene + Indazole derivative 5
|
DCVKR3P
|
Raloxifene
|
Clear cell renal cell carcinoma (Cell Line: A498)
|
[1] |
|
Raloxifene + Indazole derivative 5
|
DCN2L01
|
Raloxifene
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[1] |
|
Raloxifene + Indazole derivative 5
|
DCH740C
|
Raloxifene
|
Carcinoma (Cell Line: MCF7)
|
[2] |
|
Raloxifene + Indazole derivative 5
|
DCAQVAP
|
Raloxifene
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Raloxifene + Indazole derivative 5
|
DCUDB90
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Raloxifene + Indazole derivative 5
|
DCQ746K
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Raloxifene + Indazole derivative 5
|
DC6AENR
|
Raloxifene
|
Invasive ductal carcinoma (Cell Line: HS 578T)
|
[2] |
|
Raloxifene + Indazole derivative 5
|
DCAZJNZ
|
Raloxifene
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DC9LFMS
|
Raloxifene
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCSWG3U
|
Raloxifene
|
Adenocarcinoma (Cell Line: HCT-15)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCC5S9O
|
Raloxifene
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCX3858
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCECULE
|
Raloxifene
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCVZH0V
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCZJL9V
|
Raloxifene
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCCO7YX
|
Raloxifene
|
Large cell lung carcinoma (Cell Line: NCI-H460)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCL3LLH
|
Raloxifene
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCCMPW8
|
Raloxifene
|
Malignant melanoma (Cell Line: UACC62)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCO0NIJ
|
Raloxifene
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCO3YTC
|
Raloxifene
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DC850Z8
|
Raloxifene
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DC7E0J9
|
Raloxifene
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Raloxifene + Indazole derivative 5
|
DCYNOA7
|
Raloxifene
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DCH6F1J
|
Ruxolitinib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[1] |
|
Ruxolitinib + Indazole derivative 5
|
DCOCJA0
|
Ruxolitinib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[1] |
|
Ruxolitinib + Indazole derivative 5
|
DCS9ZF1
|
Ruxolitinib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[1] |
|
Ruxolitinib + Indazole derivative 5
|
DCQWWC4
|
Ruxolitinib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Ruxolitinib + Indazole derivative 5
|
DCQ35G4
|
Ruxolitinib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Ruxolitinib + Indazole derivative 5
|
DC33N9Z
|
Ruxolitinib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Ruxolitinib + Indazole derivative 5
|
DCOIAQY
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DC6PNCY
|
Ruxolitinib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DCEA6CM
|
Ruxolitinib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DCULUAE
|
Ruxolitinib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DCBPFDP
|
Ruxolitinib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DCFCH7V
|
Ruxolitinib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DCD7KCW
|
Ruxolitinib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DCX8ZCI
|
Ruxolitinib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DC39G4B
|
Ruxolitinib
|
Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DCR3WS5
|
Ruxolitinib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DCNFVQ5
|
Ruxolitinib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Ruxolitinib + Indazole derivative 5
|
DCGFSUI
|
Ruxolitinib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DC7W8WD
|
Vandetanib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Vandetanib + Indazole derivative 5
|
DCYRDDQ
|
Vandetanib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Vandetanib + Indazole derivative 5
|
DCXI2YP
|
Vandetanib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DCFO0GG
|
Vandetanib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DCUA68R
|
Vandetanib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DC7EDWT
|
Vandetanib
|
Chronic myelogenous leukemia (Cell Line: K-562)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DCTSQ71
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DCT3457
|
Vandetanib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DC3FF5C
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DCMMZ1J
|
Vandetanib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DCQVZNQ
|
Vandetanib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DCP31KX
|
Vandetanib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DCQVFTK
|
Vandetanib
|
Melanoma (Cell Line: MALME-3M)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DC1SBKY
|
Vandetanib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DC38O51
|
Vandetanib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DCXUB7H
|
Vandetanib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vandetanib + Indazole derivative 5
|
DCSDTIK
|
Vandetanib
|
Pleural epithelioid mesothelioma (Cell Line: NCI-H226)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCCP0TS
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Vemurafenib + Indazole derivative 5
|
DCAVL9N
|
Vemurafenib
|
Invasive ductal carcinoma (Cell Line: T-47D)
|
[2] |
|
Vemurafenib + Indazole derivative 5
|
DCGFYPI
|
Vemurafenib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCPFIWU
|
Vemurafenib
|
Adenocarcinoma (Cell Line: OVCAR3)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCLR6T2
|
Vemurafenib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC7CVQJ
|
Vemurafenib
|
Amelanotic melanoma (Cell Line: MDA-MB-435)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC4Z0RZ
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: 786-0)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCA5Z2U
|
Vemurafenib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC4GPVI
|
Vemurafenib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCCPTFX
|
Vemurafenib
|
Glioma (Cell Line: SF-539)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC4HKRM
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC9A2DD
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCEKSSN
|
Vemurafenib
|
High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCJPST8
|
Vemurafenib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCCXKGE
|
Vemurafenib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC40TN1
|
Vemurafenib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC83W8L
|
Vemurafenib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCF13QT
|
Vemurafenib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC4V7SD
|
Vemurafenib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DC3W0W3
|
Vemurafenib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
|
Vemurafenib + Indazole derivative 5
|
DCE2FD8
|
Vemurafenib
|
Prostate carcinoma (Cell Line: PC-3)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCX8AMS
|
Vismodegib
|
Breast adenocarcinoma (Cell Line: MDA-MB-468)
|
[2] |
|
Vismodegib + Indazole derivative 5
|
DCH4TZ4
|
Vismodegib
|
Colon adenocarcinoma (Cell Line: COLO 205)
|
[2] |
|
Vismodegib + Indazole derivative 5
|
DCE4S9Z
|
Vismodegib
|
Invasive ductal carcinoma (Cell Line: BT-549)
|
[2] |
|
Vismodegib + Indazole derivative 5
|
DCV1OJ8
|
Vismodegib
|
Adenocarcinoma (Cell Line: DU-145)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCL6BWE
|
Vismodegib
|
Adenocarcinoma (Cell Line: NCIH23)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCMXN3J
|
Vismodegib
|
Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCQAU75
|
Vismodegib
|
Amelanotic melanoma (Cell Line: M14)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCTK2ZT
|
Vismodegib
|
Astrocytoma (Cell Line: U251)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCV4ZSQ
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: TK-10)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCA2QGR
|
Vismodegib
|
Clear cell renal cell carcinoma (Cell Line: CAKI-1)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCWRHP8
|
Vismodegib
|
Cutaneous melanoma (Cell Line: SK-MEL-5)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DC7X3TP
|
Vismodegib
|
Cutaneous melanoma (Cell Line: SK-MEL-28)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCV4LX3
|
Vismodegib
|
Glioblastoma (Cell Line: SNB-75)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCFK8RC
|
Vismodegib
|
High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCW3R2D
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: MDA-MB-231)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCJG3EI
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: EKVX)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCOID1N
|
Vismodegib
|
Lung adenocarcinoma (Cell Line: HOP-62)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DC97S2G
|
Vismodegib
|
Melanoma (Cell Line: UACC-257)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCSW5V8
|
Vismodegib
|
Melanoma (Cell Line: SK-MEL-2)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DC4A9HY
|
Vismodegib
|
Non-small cell lung carcinoma (Cell Line: HOP-92)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DC1UX16
|
Vismodegib
|
Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DCN5VQH
|
Vismodegib
|
Papillary renal cell carcinoma (Cell Line: ACHN)
|
[3] |
|
Vismodegib + Indazole derivative 5
|
DC6UCGN
|
Vismodegib
|
Plasma cell myeloma (Cell Line: RPMI-8226)
|
[3] |
| ------------------------------------------------------------------------------------ |
|
|
|
|
